Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in PBIO?
Pressure BioSciences Inc: THE INVESTMENT CASE

Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share

The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share
INVESTMENT OVERVIEW: PBIO The Big Picture
Earlier this month, Pressure said it was moving firmly towards profitability as it unveiled record revenues for the third quarter

Pressure BioSciences Inc (OTC:PBIO) has received an upbeat write-up from Zacks smallcap research, which it reckons is more like a development stage biotech and targets US$10 each for the shares (current price: US$4.20).

The group operates in the "rather large, but underserved" research services market, says Zacks.

It has developed a "unique and superior pressure" cycling technology (PCT) to prepare biological laboratory samples.

The research group said sales had not been stellar so far, but this was "understandable".

PCT quite a new technology

"Pressure cycling technology is quite new to most customers in the sample preparation market, and the costs for PCT are also higher than those for most existing technologies. Therefore, rollout of the PCT platform will take time."

Earlier this month,  Pressure said it was moving firmly towards profitability as it unveiled record revenues for the third quarter.

It reckons this revenues growth will not only continue in the fourth quarter and beyond, but accelerate to a greater rate as new sales team begins to meet with existing and potential customers throughout the US.

Total revenue in the third quarter was up 21% to US$646,061 from US$535,334 in the same period last year, which was a new record for any quarter.

Products  and services revenue increased 21%  to US$603,726, a new quarterly record, while consumable sales increased 158% to US$84,594, again a new quarterly record.

Grant revenue increased 23% to US$42,335 in the quarter, versus 34,385 in the third quarter last year.

So far, and significantly, fourth quarter purchase orders and purchase indications (90% estimated probability of closing) through to early November have already exceeded products and services revenue for the full 2016 fourth quarter, Pressure also noted.

Poised to boost top and bottom line..?

In its note, Zacks said: "With a rapidly growing market worldwide, combined with its unique technology and broad range of product offering, the company is well positioned to boost its top line and bottom line in the coming years.

"According to our long term financial model, the company's products and services revenue will grow at a compound annual growth rate (CAGR) of 79% in the next four fiscal years from 2017 to 2020."

Pressure Biosciences will become profitable in fiscal 2019 with an EPS of $0.01, it adds.

Achieving the CE marking for the Barocycler 2320EXT in February was an important next step in the company' s commercialization plans for this powerful and enabling sample preparation instrument, highlights Zacks.

"The company recently signed agreements with several strong distribution partners in Europe, the SCIEX co-marketing agreement is entering its second year (SCIEX is a global provider of laboratory instrumentation to the life sciences area, with a large presence in Europe."

And now with a significantly expanded sales capabilities, as well as the newly established multinational co-marketing partner SCIEX, Zacks reckons revenue will grow significantly in the fourth quarter and beyond.

Our price target values the company at $11 million in market cap.

Valuation conservative..

"This valuation is still very conservative in our view. As long as the company can execute on its growth strategy correctly, we believe this goal is achievable. Patient investors will get rewarded."

Shares eased 1.18% to US$4.20 on Tuesday.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use